Clarity: increasing blood flow to the brain and stimulating acetylcholine, cutting brain fog Logic: improving communication throughout the central nervous system and cell membrane quality Energy: boosting cellular energy and blocking adenosine Motivation: increasing blood flow to the brain and boosting cellular energy Creativity: anti-anxiety and antidepressant Confidence: anti-anxiety and boosting dopamine levels They came in individually wrapped packets, six packets to a box, four boxes to a monthly shipment
These included ulcerative colitis (HR 1.11), rheumatoid arthritis (HR 1.08), autoimmune thyroiditis (HR 1.30), ankylosing spondylitis (HR 1.30), and psoriasis (HR 1.17) when compared with those receiving DPP-4is
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice ( Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice PMC ) ( Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice PMC )
Progress tracking: Offer regular body composition assessments, not just weight, to help members see their progress beyond the scale
Aim for a modest calorie deficit if fat loss is a goal (slow and steady is kinder to your skin than crash dieting)
The American Diabetes Association (ADA) 2024 Standards of Care support GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists, including tirzepatide, particularly in patients with: Established atherosclerotic cardiovascular disease or high cardiovascular risk Chronic kidney disease Need for substantial A1c reduction (tirzepatide typically reduces A1c by 1.5-2.5%) Desire to avoid weight gain or achieve weight loss Inadequate glycemic control on metformin or other oral agents Tirzepatide is not approved for type 1 diabetes or diabetic ketoacidosis